- This press release from 8 May 2008 refers to a publication by Nakanishi et al.1 which was published in the peer-reviewed Journal of Urology.
- This study demonstrates that the PROGENSATM PCA3 gene-based urine test may be clinically useful in identifying men with low-grade and/or low-volume prostate cancer for whom active surveillance would be more appropriate than aggressive treatment.
- The study also shows that the test is a more reliable method than existing diagnostic tools such as serum prostate specific antigen (PSA)1.
- Mr. Ranjan Thilagarajah, consultant urological surgeon at Broomfield Hospital, Mid Essex Health Trust commented: “more and more data is emerging that the PCA3 Score is a useful measure to fine tune the diagnosis and classification of prostate cancer. The PROGENSA PCA3 test appears to help differentiate between those that are candidates for active surveillance, and those who need aggressive treatments, making it a vital part of cutting-edge prostate cancer management.”
1) Nakanishi H, et al. PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-9
More information: Article at The Medical News